Abstract
This article briefly reviews some important issues in the management of hypertension recently published or presented in medical congresses. The main results of several large outcome clinical trials, such as the Systolic Hypertension in Europe (Syst-Eur) trial, Hypertension Optimal Treatment (HOT) study and the Captopril Prevention Project (CAPPP) study, are summarized. The results of several retrospective studies dealing with the risk of cancer associated with antihypertensive treatments are presented. Finally, the nephroprotective effects of angiotensin-converting enzyme inhibitors in the progression of nondiabetic renal disease and the controversy surrounding the cardiovascular risk associated with dihydropyridine calcium antagonists are discussed.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
